Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Current or Prior Use of a Primary OSA Therapy

Condition:   Obstructive Sleep Apnea Interventions:   Drug: TAK-925;   Drug: Placebo Sponsor:   Millennium Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials